Lisette Blumenthal

Lisette Blumenthal

Auto-generated profile, based on publicly available information

Lisette Blumenthal

Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Medicine, University of Cape Town, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2016 in JMIR Research Protocols
Verified
Journal Article
Open access
CSCari Stek
Cari Stek
CSCharlotte Schutz
Charlotte Schutz
LBLisette Blumenthal
Lisette Blumenthal
Friedrich ThienemannFriedrich Thienemann
Friedrich Thienemann
JBJozefien Buyze
Jozefien Buyze
GMGraeme Meintjes
Graeme Meintjes
Early antiretroviral therapy (ART) initiation in patients diagnosed with HIV-associated tuberculosis (TB) reduces mortality among those with the lowest CD4 counts. At the same time, both early ART and a low CD4 count heighten the risk of paradoxical TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). TB is common in patients starting ART in sub-Saharan Africa. Safe interventions that reduce the incidence or severity of TB-IRIS are needed. Prednisone has been shown to reduce symptoms and markers of inflammation when used to treat TB-IRIS. To determine whether prophylactic prednisone in patients at high risk for paradoxical TB-IRIS initiating ART reduces the incidence of TB-IRIS. We are conducting a randomized, double-blind, placebo-controlled trial of prophylactic prednisone (40 mg/day for 2 weeks, followed by 20 mg/day for 2 weeks) initiated at the same time as ART in patients at high risk for TB-IRIS (starting ART within 30 days of TB treatment and CD4 count ≤100/μL). The primary endpoint is development of TB-IRIS, defined using an international consensus case definition. Secondary endpoints include time to TB-IRIS event, severity of TB-IRIS, quality of life, mortality, hospitalization, other infections and malignancies, and adverse events including corticosteroid adverse effects. Enrollment for the trial began in August 2013. All 240 participants have been enrolled, and safety follow-up will be completed in March 2017. No preventive strategies for TB-IRIS currently exist. If results of this trial demonstrate the efficacy and safety of prednisone, this will provide clinicians with an evidence-based preventive strategy in patients at high risk for paradoxical TB-IRIS when initiating ART.

28 August 2019 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
CSCharlotte Schutz
Charlotte Schutz
AWAmy Ward
Amy Ward
RBRosie Burton
Rosie Burton
MNMark P. Nicol
Mark P. Nicol
LBLiz Blumenthal
Liz Blumenthal
AKAndrew D. Kerkhoff
Andrew D. Kerkhoff
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.